Ensovibep is shown in vitro to maintain inhibition against all variants of concern known to date The Company is also presenting a Trial in Progress poster on the EMPATHY clinical trial at the conference ZURICH -SCHLIEREN, Switzerland , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX:

ZURICH -SCHLIEREN, Switzerland , Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz

- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3

Global rights to registrational-stage ophthalmology drug return to Molecular Partners Improvements in manufacturing and formulation have been made and tested in  pre-clinical models with the potential to overcome inflammatory side effects Ongoing research discovery alliance with AbbVie in

Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 /  Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of

Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in both hospitalized and ambulatory settings ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 13, 2021

Zurich-Schlieren, Switzerland, June 9, 2021.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial public offering in the United States of 3,000,000

EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted

in vitro  studies show ensovibep (MP0420) maintains full potency against the known mutations of SARS-CoV-2, including those present in variants first identified in Brazil, California, India, and New York, in addition to the previously reported variants originating from the UK and South Africa